NCT06491563CompletedPhase 2
Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH)
A Phase 2 Multicenter, Open-label Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and Pegylated Interferon Alpha (PEG-IFNα) for the Treatment of Chronic Hepatitis B Virus (HBV) Infection (ENRICH)
Source: ClinicalTrials.gov · Last updated 21 Oct 2026
Brief summary (registry, in English)
This study will evaluate the efficacy and safety of the regimens containing BRII-179, BRII-835, and PEG-IFNα in adult participants with chronic hepatitis B virus (HBV) infection receiving nucleos(t)ide reverse transcriptase inhibitors (NRTIs) as background therapy.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 150 (actual)
- First submitted
- 28 Jun 2024
- Start date
- 6 Aug 2024
- Primary completion date
- 5 Aug 2026
- Lead sponsor
- Brii Biosciences Limited
- Diseases
- Hepatitis B
- NCT number
- NCT06491563
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 150
- From 6 Aug 2024 to the primary completion date, 5 Aug 2026
- 12 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- 3\. History or evidence of drug or alcohol abuse.
Other illness
- 1\. Any clinically significant chronic or acute medical condition that makes the participant unsuitable for participation.
- 4\. History of intolerance to SC or IM injection.
- 5\. History of chronic liver disease from any cause other than chronic HBV infection.
- 6\. History of hepatic decompensation.
Other
- 2\. Significant liver fibrosis or cirrhosis.
- 7\. Contraindications to the use of PEG-IFNα.
Who the study is looking for
- 1\. Male or female aged 18-60 years.
- 2\. Body mass index ≥ 18 kg/m2 and ≤ 32 kg/m2.
- 3\. Chronic HBV infection for ≥ 6 months.
- 4\. On NRTI therapy for ≥ 6 months.
Age in the registry: 18 years to 60 years · Sex: All · Does not accept healthy volunteers
Sites (12)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
| - Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
| - Coordinator of this site? Confirm its status | Chengdu | China | Unknown status |
| - Coordinator of this site? Confirm its status | Chengdu | China | Unknown status |
| - Coordinator of this site? Confirm its status | Foshan | China | Unknown status |
| - Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
| - Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
| - Coordinator of this site? Confirm its status | Hangzhou | China | Unknown status |
| - Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
| - Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
| - Coordinator of this site? Confirm its status | Shenzhen | China | Unknown status |
| - Coordinator of this site? Confirm its status | Xiamen | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.